MA-HARVEY-PERFORMANCE
15.7.2024 15:00:31 CEST | Business Wire | Press release
Harvey Performance Company (“Harvey Performance” or the “company”), a leading provider of specialized cutting tools for precision machining applications, today announced the acquisition of ATA. Harvey Performance serves the market through industry-leading brands Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking. ATA is an Ireland-based precision engineering multinational and the parent company of the Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, Industrial Tooling Corporation (“ITC”), and Garryson brands.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240715286290/en/
“We couldn’t be more excited about welcoming ATA to the Harvey Performance family,” said Brian Lavelle, Chief Executive Officer of Harvey Performance Company. “This acquisition represents a milestone in the proud history of the company and further establishes our integrated, international business comprised of distinctive brands and product lines.”
Since its inception as a family business in 1963, ATA has remained steadfast in its dedication to manufacturing, supplying, and distributing tools of exceptional quality. Today, it boasts a product offering exceeding 25,000 precision industrial cutting tools which it supplies to leading manufacturing industries, including aerospace, power generation, electronics, and more. ATA –which is headquartered in Ireland and has additional operating locations in the United Kingdom, United States, Germany, The Netherlands, and Switzerland – engineers, manufactures, and distributes its products globally from its seven manufacturing facilities, worldwide.
“We were immediately impressed by ATA, its global team and tremendous collection of brands,” Lavelle said. “Like all Harvey Performance brands, ATA brands have an established reputation for providing outstanding customer service and a dedication to manufacturing the industry’s highest quality products.”
Harvey Performance and ATA are both established leaders in their respective geographies, and the acquisition is expected to create a powerful combination across North America and Europe. The acquisition will bring an outstanding international platform on which Harvey Performance can continue to grow and expand. The ATA management team will continue to drive business for the company outside of the US.
“This acquisition presents great potential for Harvey Performance,” said Harvey Performance Company Senior Vice President of Sales Jerry Gleisner. “It provides Harvey Performance’s North American customers with exposure to some of the best industrial cutting tools that Europe has to offer.”
Peter Cosgrove, CEO of ATA, said, "ATA is delighted to join Harvey Performance Company, with whom we share a unified global vision for the future. We’re focused on expanding Harvey Performance's brands across Europe and beyond while introducing ATA's leading brands to Harvey Performance’s customers. I am honoured to join the Harvey Performance board. Our management team is looking forward to collaborating with our new colleagues, and our primary focus remains on driving business growth globally.”
“We are excited for the many growth opportunities enabled by the combination of Harvey Performance and ATA’s highly complementary offerings and talented leadership teams,” said Ted Rainaud, Managing Director, Berkshire Partners. “This acquisition represents a significant expansion of Harvey Performance’s product offering and geographic presence. We look forward to supporting the continued growth and expansion of the combined business.”
ATA’s investment partners Development Capital and the Ireland Strategic Investment Fund, who invested in 2017 and 2019 respectively, will exit as a result of the transaction.
Andrew Bourg, Co-founder and Director of Development Capital said, “We are delighted to see ATA attract a company the caliber of Harvey Performance, reflecting the success of the vision for the sector by the ATA management team. During the investment period we have been delighted to help ATA scale significantly and develop into an international leader in the cutting tools industry.”
Brian O’Connor, Ireland Strategic Investment Fund said, “ISIF’s investment in ATA is a clear example of its double bottom line mandate in action, investing on a commercial basis to support the scaling of an Irish indigenous business globally, and so supporting economic activity and the creation of high value employment in Ireland. Today’s announcement reflects a strong performance by the ATA team, a positive outcome for the company and a strong investment return for ISIF.”
Piper Sandler acted as exclusive financial advisor to Harvey Performance Company and Berkshire Partners on the acquisition of ATA. Houlihan Lokey acted as exclusive financial advisor to ATA.
About Harvey Performance Company
Harvey Performance Company strives to offer unique and innovative products to solve the industries’ most challenging machining requirements. Its distinct brands, Harvey Tool, Helical Solutions, Micro 100, Titan USA, CoreHog, and Valor Holemaking serve specialty needs and markets with a shared commitment to delivering high quality products and superior service. The brands offer a broad range of products and services that help support machinists, engineers, and CNC programmers while giving their shops a competitive advantage. Harvey Performance Company has a proud history of doing business the right way – offering fast, friendly service; providing comprehensive product support; and treating customers, suppliers, and shareholders in a way that builds strategic, strong, and enduring relationships. For more information, visit www.harveyperformance.com.
About ATA
ATA is an Irish headquartered manufacturer and supplier of precision cutting tools for industrial leaders around the globe. ATA serves over 7,500 customers in 90 countries. ATA was acquired in 2008 by Peter Cosgrove (CEO) and equity investors. Today the business has operating facilities located across Ireland, Germany, Switzerland, the UK, the Netherlands, and the US, and employs close to 500 people. Its leading brands Karnasch, SGSPRO, ATA Tools, Van Hoorn Carbide, and ITC and Garryson, are recognized as industry leaders throughout Europe. For more information, visit www.atagroup.com.
About Berkshire Partners
Berkshire Partners is a 100% employee-owned, multi-sector specialist investor in private and public equity. The firm’s private equity team invests in well-positioned, growing companies across services & industrials, technology & communications, consumer, and healthcare. Since inception, Berkshire Partners has made more than 150 private equity investments and has a strong history of collaborating with management teams to grow the companies in which it invests. The firm's public equity group, Stockbridge, founded in 2007, manages a concentrated portfolio seeking attractive long-term investments. The firm’s Stockbridge and Private Equity teams frequently collaborate and leverage their collective industry expertise across sectors. For additional information, visit www.berkshirepartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715286290/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
